切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2022, Vol. 10 ›› Issue (02) : 113 -118. doi: 10.3877/cma.j.issn.2095-655X.2022.02.009

临床研究

核不均一核糖核蛋白C在肺腺癌中的表达及对临床预后预测价值
高军1, 朱珍2, 李虹2, 林欣2, 宋一祎2, 孔志斌2,()   
  1. 1. 201306 上海交通大学附属第六人民医院病理科
    2. 201306 上海交通大学附属第六人民医院呼吸内科
  • 收稿日期:2021-12-16 出版日期:2022-04-26
  • 通信作者: 孔志斌
  • 基金资助:
    国家自然科学基金(82004432)

Heterogeneous nuclear ribonucleoprotein C expression in lung adenocarcinoma and its prognostic value

Jun Gao1, Zhen Zhu2, Hong Li2, Xin Lin2, Yiyi Song2, Zhibin Kong2,()   

  1. 1. Department of Pathology, Sixth People′s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 201306, China
    2. Department of Respiratory Medicine, Sixth People′s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 201306, China
  • Received:2021-12-16 Published:2022-04-26
  • Corresponding author: Zhibin Kong
引用本文:

高军, 朱珍, 李虹, 林欣, 宋一祎, 孔志斌. 核不均一核糖核蛋白C在肺腺癌中的表达及对临床预后预测价值[J/OL]. 中华诊断学电子杂志, 2022, 10(02): 113-118.

Jun Gao, Zhen Zhu, Hong Li, Xin Lin, Yiyi Song, Zhibin Kong. Heterogeneous nuclear ribonucleoprotein C expression in lung adenocarcinoma and its prognostic value[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(02): 113-118.

目的

探讨核不均一核糖核蛋白C(HNRNPC)在肺腺癌(LUAD)中的表达及对临床预后的意义。

方法

通过癌症基因组图谱数据库(TCGA)及临床蛋白质组肿瘤分析协作组(CPTAC)公共数据库,收集535例LUAD患者的临床病理资料、HNRNPC mRNA表达数据及111例LUAD患者HNRNPC蛋白表达数据,通过基因型-组织表达数据库(GETx)收集288例健康人肺组织HNRNPC mRNA表达数据。以HNRNPC mRNA中位数值为界值,将LUAD患者分为高表达组和低表达组,利用R语言比较LUAD组织与正常肺组织HNRNPC mRNA及蛋白水平的差异,分析HNRNPC mRNA高低表达与患者临床病理特征及预后的关系。运用受试者工作特征(ROC)曲线分析HNRNPC表达对LUAD的诊断价值;通过基因集富集分析(GSEA)HNRNPC调控的相关信号通路。

结果

HNRNPC mRNA在LUAD组织中的表达明显高于正常组织,差异具有统计学意义(均P<0.01);LUAD组织中HNRNPC蛋白水平也显著上调(P<0.05)。HNRNPC表达水平与LUAD患者吸烟史、临床分期、T分期、远处转移有关(均P<0.05)。Log-rank检验结果显示,HNRNPC高表达组LUAD患者中位生存期(42.3个月)明显低于低表达组患者(59.9个月),差异具有统计学意义(P<0.01)。多因素Cox回归分析显示,淋巴结转移和HNRNPC mRNA表达水平是LUAD患者预后的独立影响因素。ROC曲线示HNRNPC mRNA表达水平对诊断LUAD具有一定的预测效能,AUC为0.843,95%CI:0.817~0.869。GSEA功能富集分析示Ras相似物GTP酶(Rho GTPases)途径、TP53信号途径、DNA损伤修复、细胞周期及M期调控在HNRNPC高表达组明显富集。

结论

HNRNPC在LUAD组织中表达显著上调,高表达患者预后不良,HNRNPC可能是评估LUAD患者诊断与预后的新的潜在生物学分子标志物。

Objective

To investigate the expression of heterogeneous nuclear ribonucleoprotein C(HNRNPC) and discuss its clinical significance in lung adenocarcinoma(LUAD).

Methods

The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) public databases were used to collect clinicopathological data and HNRNPC mRNA expression data from 535 patients with LUAD, as well as protein expression data from 111 patients with LUAD. The Genotype-tissue expression (GETx) database was used to obtain HNRNPC mRNA expression data from 288 healthy lung tissues. Based on the median value of HNRNPC mRNA level as the boundary value, LUAD patients were divided into high expression group and low expression group. By the R programming language, the difference of mRNA and protein levels of HNRNPC in LUAD and normal lung tissues were compared, and the link between HNRNPC mRNA expression and clinicopathological characteristics and patient prognosis was investigated. Receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of HNRNPC expression in lung adenocarcinoma. Gene set enrichment analysis (GSEA) was used to look into the relevant signaling pathways regulated by HNRNPC.

Results

The expression of HNRNPC mRNA in LUAD was significantly higher than that in normal lung tissues (all P<0.01). The protein expression level of HNRNPC in LUAD was also significantly up-regulated (P<0.05). Univariate analysis showed that the expression of HNRNPC mRNA was correlated with smoking history, clinical stage, T stage and distant metastasis(all P<0.05). Log-rank test showed that the median survival time of patients with LUAD in the HNRNPC high expression group (42.3 months) was significantly lower than that in the low expression group (59.9 months) (P<0.01). The multivariate Cox regression analysis revealed that lymph node metastasis and the high expression of HNRNPC mRNA were independent prognostic factors of LUAD. ROC curve analysis showed that HNRNPC mRNA expression level could predict the diagnosis of LUAD (AUC=0.843, 95%CI=0.817-0.869). GSEA showed that Rho GTPases pathway, TP53 signaling pathway, DNA repair, cell cycle and M phase regulation were significantly enriched in HNRNPC highly expressed phenotype.

Conclusions

The expression level of HNRNPC in LUAD is significantly higher than that in normal lung tissue, and high HNRNPC expression group indicates poor prognosis in patients with LUAD. HNRNPC maybe a novel potential biomarker for the diagnosis and prognosis of patients with LUAD.

图1 HNRNPC mRNA在肺腺癌组织与正常肺组织中的表达情况注:a图为TCGA非配对样本,肺腺癌组(n=535)HNRNPC mRNA表达水平高于癌旁正常组(n=59)(P<0.01);b图为TCGA+GETx非配对样本,肺腺癌组(n=515)HNRNPC mRNA表达水平高于健康正常组(n=288例)及癌旁正常组(n=59)(P<0.01);c图为TCGA配对样本,配对样本肺腺癌组(n=57)HNRNPC mRNA表达水平高于癌旁正常组(n=57)(P<0.01); HNRNPC为核不均一核糖核蛋白C;LUAD为肺腺癌;TCGA为癌症基因组图谱数据库;GETx为基因型-组织表达数据库;正常肺组织为癌旁正常组织和(或)健康对照者的肺组织;肿瘤为肺腺癌组织
图2 HNRNPC在肺腺癌组织与正常肺组织中的蛋白表达情况注:CPTAC数据库中,肺腺癌组(n=111)HNRNPC蛋白表达水平明显高于癌旁正常组(n=111);Z值表示给定癌症类型的样本中位数的标准化;正常肺组织为癌旁正常组织,肿瘤为肺腺癌组织;HNRNPC为核不均一核糖核蛋白C;CPTAC为临床蛋白质组肿瘤分析协作组数据库
表1 HNRNPC mRNA表达与肺腺癌患者临床病理特征比较(例)
图3 不同HNRNPC mRNA表达组肺腺癌患者总生存曲线图注:两组总生存期比较,χ2=11.35,HR=1.65(1.23~2.21),P=0.001;HNRNPC为核不均一核糖核蛋白C
表2 HNRNPC mRNA表达与肺腺癌患者预后的关系
图4 HNRNPC mRNA表达水平诊断肺腺癌的ROC曲线注:HNRNPC为核不均一核糖核蛋白C;ROC为受试者工作特征
[1]
Sung H, Ferlay J, Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin202171(3):209-249.DOI:10.3322/caac.21660.
[2]
郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志201941(1):19-28. DOI:10.3760/cma.j.issn.0253-3766.2019.01.008.
[3]
中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J].中华医学杂志2021101(23):1725-1757.DOI:10.3760/cma.j.cn112137-20210207-00377.
[4]
Denisenko TV, Budkevich IN, Zhivotovsky B.Cell death-based treatment of lung adenocarcinoma[J].Cell Death Dis20189(2):117.DOI:10.1038/s41419-017-0063-y.
[5]
Minguet J, Smith KH, Bramlage P.Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives [J].Int J Cancer.2016138(11):2549-2561. DOI:10.1002/ijc.29915.
[6]
Love MI, Huber W, Anders S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J].Genome Biology201415(12):550. DOI:10.1186/s13059-014-0550-8.
[7]
Yu G, Wang LG, Han Y,et al.clusterProfiler: an R package for comparing biological themes among gene clusters[J].Omics201216(5):284-287.DOI:10.1089/omi.2011.0118.
[8]
Subramanian A, Tamayo P, Mootha VK,et al.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles[J].Proc Natl Acad Sci USA2005102(43):15545-15550.DOI:10.1073/pnas.0506580102.
[9]
Evers L, Messow CM.Sparse kernel methods for high-dimensional survial data[J].Bioinformatics200824(14):1632-1638.DOI:10.1093/bioinformatics/btn253.
[10]
Guo W, Huai Q, Zhang G,et al.Elevated heterogeneous nuclear ribonucleoprotein C expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma[J].Front Oncol2021(10):598437.DOI:10.3389/fonc.2020.598437.
[11]
Park YM, Hwang SJ, Masuda K, et al. Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4[J].Mol Cell Biol201232(20):4237-4244.DOI:10.1128/MCB.00443-12.
[12]
Wang LC, Chen SH, Shen XL,et al.M6A RNA methylation regulator HNRNPC contributes to tumorigenesis and predicts prognosis in glioblastoma multiforme[J].Front Oncol2020(10):536875. DOI:10.3389/fonc.2020.536875.
[13]
Zhang Y, Chen W, Pan T,et al.LBX2-AS1 is activated by ZEB1 and promotes the development of esophageal squamous cell carcinoma by interacting with HNRNPC to enhance the stability of ZEB1 and ZEB2 mRNAs[J].Biochem Biophys Res Commun2019511(3):566-572.DOI:10.1016/j.bbrc.2019.02.079.
[14]
Huang H, Han Y, Zhang C,et al.HNRNPC as a candidate biomarker for chemoresistance in gastric cancer[J].Tumour Biol201637(3):3527-3534.DOI:10.1007/s13277-015-4144-1.
[15]
Hu J, Cai D, Zhao Z,et al.Suppression of heterogeneous nuclear ribonucleoprotein C inhibit hepatocellular carcinoma proliferation,migration,and invasion via Ras/MAPK signaling pathway[J].Front Oncol2021(11):659676.DOI:10.3389/fonc.2021.659676.
[16]
Su Z, Liu X, Xu Y,et al.Novel reciprocal fusion genes involving HNRNPC and RARG in acute promyelocytic leukemia lacking RARA rearrangement[J].Haematologica2020105(7):e376-e378.DOI:10.3324/haematol.2019.244715.
[17]
Ying P, Li Y, Yang N.et al.Identification of genetic variants in m6A modification genes associated with pancreatic cancer risk in the Chinese population[J].Arch Toxico202195(3):1117-1128.DOI:10.1007/s00204-021-02978-5.
[18]
Hodge RG, Ridley AJ.Regulating Rho GTPases and their regulators[J].Nat Rev Mol Cell Biol201617(8):496-510.DOI:10.1038/nrm.2016.67.
[19]
Jiang M, Jia K, Wang L,et al.Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy[J].Acta Pharm Sin B202111(10):2983-2994.DOI:10.1016/j.apsb.2021.01.003.
[20]
Duffy MJ, Synnott NC, Crown J.Mutant p53 as a target for cancer treatment[J].Eur J Cancer2017(83):258-265.DOI:10.1016/j.ejca.2017.06.023.
[21]
Shen Y, Liu S, Fan J,et al.Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNPC-p53 protein interactions[J].EMBO Rep201718(4):536-548.DOI:10.15252/embr.201643139.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[6] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[7] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[8] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[9] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[10] 丁富贵, 吴泽涛, 董卫国. 家族性腺瘤性息肉病临床特征及生物信息学分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 512-518.
[11] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[12] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[13] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要